Resilience Enhances Clinical And Commercial Drug Product Mfg Capabilities
Resilience Expands Drug Product Manufacturing Capabilities
Resilience Partners With Taiwan Bio-Mfg Corp For Biomanufacturing Innovation
CONROE, Texas, Jan. 24, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, have entered a strategic multi-year partnership.
Resilience to Present at the 42nd Annual J.P. Morgan Healthcare Conference
National Resilience was handed a Form 483 in November noting that the manufacturer did not properly review or address mold-contaminated product batches, and it may undergo more layoffs this year, a source familiar with the matter told Endpoints News.
National Resilience has laid off staff from its technical R&D and quality assurance global divisions in recent months, Endpoints News has learned.
After multiple expansion forays overseas this year, biomanufacturing outfit National Resilience is returning to its American roots with plans to beef up production and add hundreds of new jobs at a recently purchased plant in Ohio.
Resilience Appoints Bill Marth as President of Services
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments